Breast Cancer Research Trust NZ, gaining knowledge and saving lives

Open clinical trials

The Breast Cancer Research Trust currently has the following clinical trials open to new patients:

The EXPERT Trial

Find out about Breast Cancer Research Trust EXPERT trial

The EXPERT clinical trial is a randomised phase 3 trial open to women aged 50 years or older, with Hormone Receptor (HR) positive, Human Epidermal Growth Factor Receptor 2 (HER2) negative, early stage breast cancer. EXPERT uses a genomic test of breast cancer tissue to select women who can safely avoid radiation therapy. The trial aims to improve personalised use of radiation therapy in early breast cancer patients, according to individual risk of local recurrence.

For more information contact: Jenni Scarlet, Research Nurse
Email: Jenni.Scarlet@waikatodhb.health.nz
Phone: 07 839 8726 ext 97916

Learn more about EXPERT here.

ABCpro Study

A study evaluating a new online service for managing self-reported symptoms by women with advanced breast cancer

This is study evaluating a new service where patients complete weekly online surveys about common symptoms of advanced breast cancer (ABC) and side effects associated with ABC treatments. The survey responses are then sent to an ABC nurse who will use the responses to assist patients to better manage symptoms and side effects from home in between regular clinic visits. The survey responses will also help the patient's oncology team to decide if further tests or treatments are needed.

A study to compare GDC-9545 plus palbociclib versus letrozole plus palbociclib in people with estrogen receptor-positive, HER2-negative metastatic breast cancer

GDC-9545 (also known as giredestrant) is an investigational new drug designed to block the female sex hormone called estrogen that contributes to the growth and progression of estrogen receptor-positive breast cancer. Investigational means that the drug has not been approved by health authorities for cancer treatment or treatment of any other disease. Palbociclib (IBRANCE and letrozole the two other drugs being used in this study, are currently approved therapies in New Zealand for estrogen receptor-positive metastatic breast cancer).

The purpose of this study is to compare the effects, good or bad, of GDC-9545 given in combination with palbociclib versus letrozole given in combination with palbociclib, on patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer. We need to find out which combination works best for ER positive breast cancer that has spread to other parts of the body, find out more about side effects, and how treatments affect quality of life.